TL;DR
Get oils, diffusers and self-care delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
Moderna’s mRNA flu vaccine, mFlusiva, is approved for adults 50 and older, but supply is limited this season because approval came after pharmacy orders were placed. The company says it is available at more than 13,000 locations; use its vaccine finder or call nearby pharmacies to check availability. Experts say evidence has not yet established whether it provides better clinical protection than enhanced flu vaccines.
Moderna’s mRNA flu vaccine, mFlusiva, is available in limited quantities this season after receiving FDA approval in August, too late for major pharmacy chains to include it in their earlier vaccine orders. The vaccine is approved for adults 50 and older; Moderna says it is stocked at more than 13,000 locations, but people seeking a dose may need to use the company’s vaccine finder or call pharmacies directly.
A Moderna spokesperson told MedPage Today the company planned a “limited launch in year one” and said mFlusiva was available at more than 13,000 locations. The company provided the publication with a link to its vaccine finder. The report does not specify how many doses are available at each location, so a listing may not confirm that a nearby pharmacy has an appointment or dose in stock.
Amesh Adalja, MD, of the Johns Hopkins Center for Health Security, said that people who want mFlusiva may have to use the website or call around. He told MedPage Today that pharmacies often order standard flu vaccines without distinguishing among newer products, which can make specific vaccines harder to locate.
Those who cannot find mFlusiva can ask a clinician or pharmacist about other flu vaccines. Options include standard-dose vaccines, the nasal-spray FluMist, and enhanced vaccines such as Flublok, Flucelvax, Fluzone High-Dose and Fluad. Eligibility differs by product; for example, Fluzone High-Dose and Fluad are approved for people 65 and older. A pharmacist or clinician can confirm which products are appropriate and available.
Limited Stock Shapes Vaccine Choice
The short supply means that people who specifically want an mRNA flu vaccine may have fewer convenient options than those seeking a standard product. It also comes as influenza has started early in many parts of the United States, according to William Schaffner, MD, of Vanderbilt University. Readers who cannot locate mFlusiva should not assume that no flu vaccine is available: other products may be accessible locally, and the choice can be discussed with a health professional.
Availability is only one consideration. Evidence cited in the report does not yet establish whether mFlusiva provides better clinical protection than enhanced flu vaccines. Schaffner said the shot appears to cause more short-term reactions than standard flu vaccines, including injection-site pain, fatigue, headache and muscle aches. Patients can weigh those potential reactions against their preferences and discuss questions with a clinician.
As an affiliate, we earn on qualifying purchases.
Approval Came After Pharmacy Orders
Moderna’s flu shot received FDA approval in August 2026, after national retail pharmacy chains had placed orders for the season’s vaccines. The late timing is the stated reason availability is limited in the vaccine’s first year. The FDA approved it for adults ages 50 to 64 through traditional approval and for people 65 and older through accelerated approval, with a postmarketing effectiveness study planned for the older group.
The evidence picture remains incomplete. A phase III study compared mFlusiva with a standard-dose vaccine, a comparison that drew criticism because it did not use an enhanced vaccine. A separate study found a stronger immune response than Fluzone High-Dose among people 65 and older, but it did not measure clinical outcomes. The report says all U.S. flu vaccines are now trivalent after the CDC determined that the B/Yamagata lineage had stopped circulating after March 2020.
““If someone wants to get mFlusiva, they’re going to have to use that website or call around.””
— Amesh Adalja, MD, Johns Hopkins Center for Health Security, speaking to MedPage Today
Protection and Local Stock Remain Unclear
The company’s reported figure of more than 13,000 locations does not show how many doses each site has, whether stock is current or whether appointments are available. Check directly with the pharmacy before traveling. The report also does not provide a location-by-location inventory or say how quickly supply may be replenished.
It remains unclear whether mFlusiva offers better real-world protection than enhanced flu vaccines. The studies described measure immune responses or compare the shot with a standard-dose vaccine, rather than establishing superior clinical outcomes against an enhanced product. The FDA’s planned postmarketing effectiveness study for adults 65 and older is intended to add evidence, but its timing and results are not specified in the report.
Check Stock and Watch for Study Results
People seeking mFlusiva can start with Moderna’s vaccine finder, then call the listed pharmacy to confirm that doses remain and ask about eligibility and appointments. If it is unavailable, ask a pharmacist or clinician about other suitable flu vaccines rather than delaying the discussion while searching for one brand.
Further evidence will depend on the planned postmarketing effectiveness study in adults 65 and older, particularly whether it can compare mFlusiva with an enhanced vaccine. For now, the report’s experts advise getting an available flu vaccine; the best choice for an individual can depend on age, health circumstances, product availability and personal preference.
Key Questions
Who is eligible for Moderna’s mRNA flu shot?
mFlusiva is approved for adults ages 50 and older, according to the report. Ask a pharmacist or clinician to confirm eligibility and whether the product is available to you.
How can I find a dose?
Use the Moderna vaccine finder referenced in the report, then contact the pharmacy to confirm current stock and appointment availability. The company’s reported count of more than 13,000 locations does not guarantee that every listed site has doses on hand.
Does mFlusiva provide better protection than other flu vaccines?
That has not been established. Studies reported stronger immune responses in some comparisons, but the evidence described does not show that mFlusiva provides better clinical protection than enhanced flu vaccines.
What if I cannot find mFlusiva?
Ask a pharmacist or clinician about other available flu vaccines that fit your age and circumstances. Options include standard-dose and enhanced vaccines, but approval and eligibility vary by product.
Source: rss
Halloween Picks
halloween
As an affiliate, we earn on qualifying purchases.
